EN DE
Watch Greenway Greenhouse Cannabis Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Greenway Greenhouse Cannabis Corporation (GWAYF) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of Greenway Greenhouse Cannabis Corporation stock $0.05, price $0.06, that is 8.3% below the price, quality 30 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA39679F2035

GG Greenway Greenhouse Cannabis Corporation logo Thin data Nov 10, 2026

Greenway Greenhouse Cannabis Corporation

GWAYF · US

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +38% vs. a year ago. 
Fair value $0.0531 · Fairly valued 
Expensive Growth (revenue 5y +45.1 %/yr in CAD) 
Mixed vs. peers (4/10) 
Quality 30/100 
Falling price (downtrend) 
Loss-making · -37.9% net margin (TTM) 
Negative free cash flow 
Narrow moat 6/100 · thin data
Thin data 
Estimate⚠ Thinly traded
Watch Greenway Greenhouse Cannabis Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.3562 $0.0517 Fair Value $0.0531 Jan 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

46‑month range $0.0517 – $0.3562 · fair‑value band $0.0461 – $0.0602 · the $0.0579 price screens above the $0.0531 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Greenway Greenhouse Cannabis in your weekly email

Every Wednesday you see whether Greenway Greenhouse Cannabis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Greenway Greenhouse Cannabis Corporation engages in the cultivation, processing, sale, bulk package, and wholesale of dry bud cannabis. The company was incorporated in 2018 and is headquartered in Kingsville, Canada. Greenway Greenhouse Cannabis Corporation is a subsidiary of Sunrite Greenhouses Ltd.

Stock analysis

Greenway Greenhouse Cannabis Corporation (GWAYF) currently trades at $0.0579, while our estimate is $0.0531, so the stock looks roughly fairly valued today (gap 9.1%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.0461 (bear) to $0.0602 (bull), the price of $0.0579 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Greenway Greenhouse Cannabis Corporation reported revenue of C$7.4M in FY2026 versus C$2.0M in FY2022, a compound +39.2%/yr. Reported net income was −C$2.6M in FY2026.

Key figures

Market cap $7.7M Micro · P/S ratio 0.98 · EPS (TTM) $−0.0100 · Net margin −34.4% · Return on equity −35.8% · Return on assets (EBIT) −5.7% (5-year average) · Operating margin −15.8% · Revenue (TTM) C$8.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 79% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −8%, GWAYF screens cheaper than that median.

Fair Value

Bear $0.0461 Fair Value $0.0531 Bull $0.0602
Price $0.0579 · Downside -8.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 16
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 22
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 74
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−16.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.1%
Start year 2021 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−107.4% (2021) → −19.4% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch GWAYF, get fair value alerts →

Compare Greenway Greenhouse Cannabis Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −8.3% · Above median
Profitability
Return on assets −8.3% · Bottom 25%
Net margin (12 months) −37.9% · Bottom 25%
Operating margin (12 months) −15.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 37.7% · Top 25%
Balance sheet
Debt / equity 0.36× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.42× · Cheaper than median
P/S (12 months) 1.37× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)82 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs GWAYF
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs GWAYF
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs GWAYF
Haleon plc HLN $9.17 $8.62 −6% vs GWAYF
Merck KGaA MRK €149.60 €108.83 −27% vs GWAYF
Galderma Group GALD CHF 191.40 CHF 111.92 −42% vs GWAYF
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs GWAYF
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs GWAYF
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs GWAYF
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs GWAYF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Greenway Greenhouse Cannabis Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Greenway Greenhouse Cannabis Corporation Fair Value". https://www.fairvalue-calculator.com/stock/GWAYF

Frequently asked questions

Is Greenway Greenhouse Cannabis Corporation (GWAYF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.0531 versus a price of $0.0579, about 8% lower (fairly valued).
What is the fair value of GWAYF?
Our estimate for Greenway Greenhouse Cannabis Corporation is $0.0531 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.0579.
What is the quality score of GWAYF?
Greenway Greenhouse Cannabis Corporation has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Greenway Greenhouse Cannabis Corporation (GWAYF)?
Our calculated price target is the estimate of $0.0531 (as of Nov 10, 2026). Cautious scenario $0.0461, optimistic scenario $0.0602. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Greenway Greenhouse Cannabis Corporation stock forecast for 2026?
Our estimate puts fair value at $0.0531, about 8% lower versus a price of $0.0579 (fairly valued). Cautious scenario $0.0461, optimistic scenario $0.0602. The calculation is refreshed regularly with new filings.
What is the revenue of Greenway Greenhouse Cannabis Corporation (GWAYF)?
Greenway Greenhouse Cannabis Corporation reported trailing-twelve-month revenue of about C$8.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Greenway Greenhouse Cannabis Corporation (GWAYF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Greenway Greenhouse Cannabis Corporation it is $0.0531 per share (as of Nov 10, 2026), against a price of $0.0579.
Is Greenway Greenhouse Cannabis Corporation stock overvalued or undervalued in 2026?
As of Nov 10, 2026, GWAYF trades above its calculated fair value: price $0.0579, fair value $0.0531, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GWAYF?
No. The price is what the market pays today ($0.0579); the fair value is what the company's own numbers justify ($0.0531). For Greenway Greenhouse Cannabis Corporation the two are $0.0048 per share apart. That gap is exactly why we show both numbers side by side.
How much is Greenway Greenhouse Cannabis Corporation worth?
The market values Greenway Greenhouse Cannabis Corporation at about $7.7M (market capitalisation, as of Nov 10, 2026). Per share that is $0.0579; our models calculate a fair value of $0.0531 per share.
What do the bullish and bearish scenarios say about GWAYF?
Our models span a range for Greenway Greenhouse Cannabis Corporation: cautious scenario $0.0461, base $0.0531, optimistic $0.0602 per share (as of Nov 10, 2026, price $0.0579). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Greenway Greenhouse Cannabis Corporation (GWAYF)?
Balance-sheet figures for Greenway Greenhouse Cannabis Corporation (as of Nov 10, 2026): return on equity −35.8%, debt of 0.36 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is GWAYF from its 52-week high?
Greenway Greenhouse Cannabis Corporation trades at $0.0579, about 79% below its 52-week high of $0.2705 and 12% above the low of $0.0517 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0531 is for.
Which stocks are comparable to Greenway Greenhouse Cannabis Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Greenway Greenhouse Cannabis Corporation stock attractive at the current price?
The data as of Nov 10, 2026: price $0.0579, calculated fair value $0.0531 (−8%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Greenway Greenhouse Cannabis Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The closing price on Nov 12, 2026 was $0.0579. Our estimate is $0.0531, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Greenway Greenhouse Cannabis Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Greenway Greenhouse Cannabis Corporation

How large is the market capitalisation of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The market capitalisation of Greenway Greenhouse Cannabis Corporation is $7.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The price-to-sales ratio of Greenway Greenhouse Cannabis Corporation is 0.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Greenway Greenhouse Cannabis Corporation (GWAYF)?
Earnings per share at Greenway Greenhouse Cannabis Corporation are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The net margin of Greenway Greenhouse Cannabis Corporation is −34.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The return on equity (ROE) of Greenway Greenhouse Cannabis Corporation is −35.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Greenway Greenhouse Cannabis Corporation (GWAYF)?
On an EBIT basis the return on assets of Greenway Greenhouse Cannabis Corporation is −5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The operating margin of Greenway Greenhouse Cannabis Corporation is −15.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Greenway Greenhouse Cannabis Corporation (GWAYF)?
Revenue at Greenway Greenhouse Cannabis Corporation is growing +37.7% versus a year earlier (3y avg +9.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Greenway Greenhouse Cannabis Corporation (GWAYF) generate?
The free cash flow of Greenway Greenhouse Cannabis Corporation is −C$2.0M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Greenway Greenhouse Cannabis Corporation (GWAYF) carry?
The net debt of Greenway Greenhouse Cannabis Corporation is C$6.6M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Greenway Greenhouse Cannabis Corporation in the live analysis

One click puts Greenway Greenhouse Cannabis Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.